Onyx to Support Charity on Multiple Projects
Cancer Research UK is using Onyx Scientific to manage several of its drug development projects in a bid to maximise value for the UK’s leading cancer charity.
The UK-based contract research organisation is now supporting the charity across a portfolio of drug substance campaigns covering the development and manufacturing of API for use in clinical trials.
Across the range of projects, Cancer Research UK’s Drug Development Office is utilising the contract manufacturing organisation’s (CMO) expertise in: process development, solid-state chemistry, analytical and GMP synthesis of API for use in Phase I clinical trials.
Cancer Research UK’s Drug Development Office initially selected the chemistry specialist for a GMP synthesis project in 2011. There have been further successful GMP campaigns since that first project. Onyx Scientific is one of the Charity’s preferred providers for API development and GMP synthesis, which has resulted in a greater volume of work being placed with Onyx because of the quality of their work, GMP compliance, excellent communication and ‘can do’ attitude.
Dr Nigel Westwood, drug supply manager at Cancer Research UK, said: “Over the last few years, the team at Onyx Scientific has worked proactively with us on several challenging synthetic chemistry projects and provided exceptional value for money, which has led to us to select them for several new projects based on their competitive costs and ability to delivery on time.
“Having sufficient quantities of API available in a timely manner is critical for our drug development activities. Onyx Scientific is a reliable partner that can meet deadlines and deal with complex chemistry in a cost effective manner.
“It therefore makes total sense for our organisation to work even more closely with Onyx Scientific as a partner to assist with the process development, solid-state characterisation and GMP manufacture of API across several compounds,” added Dr Westwood.
With MHRA and FDA inspected facilities in the UK and India, IPCA Laboratories owned Onyx Scientific assists companies with medicinal chemistry and preclinical development through Phase I-III, scaling-up to large scale API production.
The CMO’s UK-based laboratories deal with challenging chemistry to deliver early stage programs and is then able to scale-up, tech transfer and increase project efficiency using its parent company’s commercial manufacturing sites in India.
Denise Bowser, commercial director at Onyx Scientific, said: “Our team has developed an excellent partnership with Cancer Research UK and so we are naturally delighted to be working with them on such a raft of important projects.
“It is very pleasing that our track-record and reputation in solid state chemistry and GMP API manufacturing continues to grow. This has led to us to work with several of the biggest pharmaceutical companies in the world alongside many smaller drug developers and charitable bodies.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance